Novavax (NVAX) Total Debt (2010 - 2026)

Novavax's (NVAX) quarterly Total Debt came in at $291.0 million in Q1 2026, up 19.17% quarter-over-quarter from $244.2 million in Q4 2025.

Novavax (NVAX) Total Debt (2010 - 2026) Analysis & Trends

Novavax's Total Debt history runs 8 years deep, the most recent figure standing at $291.0 million for Q1 2026.

On a quarterly basis, Total Debt changed N/A year-over-year to $291.0 million in Q1 2026; TTM through Mar 2026 was $291.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $244.2 million, changed N/A from the prior year.
Total Debt climbed to $291.0 million in Q1 2026 per NVAX's latest filing, from $244.2 million in the prior quarter.
Across five years, Total Debt topped out at $291.0 million in Q1 2026 and bottomed at $244.2 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	110.96 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	959.06 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	1.99 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Novavax	788.01 Mn	-2.33 Mn	108.82 Mn	291.04 Mn

Download Data